Profile data is unavailable for this security.
About the company
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
- Revenue in USD (TTM)14.15bn
- Net income in USD1.52bn
- Incorporated2021
- Employees24.00k
- LocationHaleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
- Phone+44 193 282 2000
- Websitehttps://www.haleon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | 9.61bn | 1.62bn | 23.03bn | 7.57k | 14.28 | 1.40 | 10.17 | 2.40 | 11.07 | 11.07 | 65.83 | 112.90 | 0.34 | 0.8604 | 4.58 | 1,269,155.00 | 5.71 | 12.53 | 7.01 | 14.83 | 75.59 | 83.04 | 16.80 | 26.93 | 0.8039 | 4.89 | 0.2778 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.09bn | -332.26m | 31.83bn | 2.10k | -- | 982.81 | -- | 15.20 | -2.62 | -2.62 | 16.52 | 0.2511 | 0.5208 | 3.57 | 8.41 | 997,521.40 | -8.26 | -26.56 | -11.31 | -32.77 | 85.37 | 83.66 | -15.86 | -94.26 | 2.69 | -1.36 | 0.9694 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Otsuka Holdings Co Ltd | 14.69bn | 980.85m | 32.31bn | 34.39k | 32.03 | 1.93 | 18.98 | 2.20 | 279.51 | 279.51 | 4,183.34 | 4,641.15 | 0.647 | 2.40 | 4.68 | 65,998,690.00 | 4.42 | 4.80 | 5.59 | 5.88 | 71.42 | 68.21 | 6.84 | 8.36 | 1.53 | -- | 0.1173 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| UCB SA | 5.71bn | 251.39m | 35.48bn | 9.08k | 141.56 | 3.69 | 36.27 | 6.21 | 1.23 | 1.23 | 27.92 | 47.19 | 0.3518 | 1.71 | 4.26 | 600,462.40 | 1.55 | 5.03 | 1.88 | 6.28 | 67.80 | 72.21 | 4.40 | 12.66 | 0.7806 | 3.15 | 0.2534 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Takeda Pharmaceutical Co Ltd | 29.42bn | 1.88bn | 42.43bn | 49.28k | 22.66 | 0.9439 | 6.25 | 1.44 | 181.90 | 181.90 | 2,862.68 | 4,365.91 | 0.3088 | 1.31 | 6.25 | 92,248,190.00 | 1.97 | 1.65 | 2.35 | 1.97 | 66.05 | 68.05 | 6.38 | 6.06 | 0.7739 | 3.08 | 0.4219 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
| Haleon PLC - ADR | 14.15bn | 1.52bn | 42.65bn | 24.00k | 18.02 | -- | 180.25 | 3.01 | 0.530 | 0.530 | 3.61 | -- | -- | -- | -- | 589,447.00 | -- | -- | -- | -- | 61.94 | -- | 11.21 | -- | -- | 7.59 | -- | -- | 4.09 | -- | -1.04 | -- | -- | -- |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.59bn | 752.78m | 44.24bn | 19.61k | 59.06 | 7.32 | -- | 12.32 | 0.8499 | 0.8499 | 4.06 | 6.86 | 0.57 | 1.57 | 4.60 | 1,325,555.00 | 11.94 | 13.68 | 12.99 | 15.20 | 84.88 | 85.87 | 20.94 | 20.01 | 8.34 | -- | 0.002 | 23.77 | 7.26 | 5.55 | 10.14 | 1.14 | 22.90 | 9.45 |
| Sun Pharmaceutical Industries Ltd | 5.95bn | 1.31bn | 50.54bn | 43.00k | 38.59 | 6.18 | 31.20 | 8.49 | 46.12 | 46.12 | 209.89 | 288.06 | 0.6005 | 1.05 | 4.15 | 11,699,470.00 | 13.29 | 7.77 | 16.92 | 10.85 | 79.15 | 71.59 | 22.14 | 14.23 | 2.09 | -- | 0.0358 | 38.64 | 10.51 | 10.78 | 13.01 | 29.15 | -7.28 | 37.47 |
| Daiichi Sankyo Co Ltd | 11.38bn | 1.62bn | 56.48bn | 18.73k | 34.26 | 5.24 | 27.70 | 4.96 | 130.86 | 130.86 | 918.60 | 855.86 | 0.5913 | 1.01 | 3.73 | 93,883,960.00 | 8.43 | 4.99 | 10.51 | 6.14 | 76.11 | 69.10 | 14.26 | 9.94 | 2.24 | -- | 0.0589 | 51.87 | 25.28 | 11.49 | 85.90 | 16.67 | 13.01 | 16.47 |
| Merck KGaA | 21.96bn | 2.82bn | 62.98bn | 62.26k | 22.29 | 2.12 | 13.29 | 2.87 | 6.21 | 6.21 | 48.25 | 65.14 | 0.4191 | 1.85 | 4.98 | 333,232.70 | 5.41 | 5.64 | 6.70 | 7.27 | 58.60 | 61.86 | 12.90 | 12.97 | 0.9103 | 54.78 | 0.2861 | 9.26 | -5.57 | 7.19 | -15.09 | 21.40 | 14.77 | 11.97 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 30 Sep 2024 | 179.17m | 3.96% |
| Strategic Advisers LLCas of 30 Sep 2024 | 56.85m | 1.26% |
| ClearBridge Investments LLCas of 30 Sep 2024 | 37.37m | 0.83% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 34.17m | 0.76% |
| Harding Loevner LPas of 30 Sep 2024 | 24.89m | 0.55% |
| FIAM LLCas of 30 Sep 2024 | 13.90m | 0.31% |
| Fisher Asset Management LLCas of 30 Sep 2024 | 13.68m | 0.30% |
| Aristotle Capital Management LLCas of 30 Sep 2024 | 8.99m | 0.20% |
| Sculptor Capital LPas of 30 Sep 2024 | 8.89m | 0.20% |
| Douglas Lane & Associates LLCas of 30 Sep 2024 | 8.46m | 0.19% |
